Assets
(4 total)
4Total Assets
0Approved
0Phase 3 / Filed
4Phase 1–2 / Early
3Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | 5-HT2A receptorSmall molecule | Major Depressive Disorder Treatment-Resistant Depression | |
| Phase 2 | Undisclosed / early pipeline | Schizophrenia Cognitive Impairment Associated with Schizophrenia | |
| Phase 2 | 5-HT2A receptorSmall molecule | Major Depressive Disorder Treatment-Resistant Depression | |
| Preclinical / Unstaged | —Small molecule | Social Anxiety Disorder |
Upcoming events
Research
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.